Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thick filament molecular interfaces play a critical role in the pathogenesis of hypertrophic cardiomyopathy.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Apelin analog treatment reverses severe pulmonary arterial hypertension and right ventricular heart failure.

JCI insight·2026

Same author

Targeting Inflammation by Pioglitazone and its R-Enantiomer Mitigates Pathological Myocardial Remodeling in Murine Hypertrophic Cardiomyopathy.

JACC. Basic to translational science·2026

Same author

Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis.

Circulation·2026

Same author

Sex and Age Specific Genetic Risk Across the Dilated and Arrhythmogenic Cardiomyopathy Spectrum: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026

Same author

Rare <i>KDR</i> Variants Define a Distinct Genetic Contribution to Congenital Heart Disease.

Circulation. Genomic and precision medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Dual-Dye Optical Mapping of Hearts from RyR2^R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.

Guy Katz¹, Assad Khoury, Efrat Kurtzwald

¹Heart Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Israel.

|July 13, 2010

Summary

Verapamil effectively treats catecholamine-induced arrhythmias in a mouse model of CPVT2. Combining verapamil with beta-blockers may improve treatment for human patients with this condition.

More Related Videos

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Related Experiment Videos

Last Updated: Jun 11, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Dual-Dye Optical Mapping of Hearts from RyR2^R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Area of Science:

Cardiology
Genetics
Pharmacology

Background:

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening arrhythmia triggered by stress.
Current beta-adrenergic blockers are ineffective in up to 50% of CPVT patients.

Purpose of the Study:

To optimize antiarrhythmic therapy for recessively inherited CPVT caused by calsequestrin (CASQ2) mutations.
To evaluate the efficacy of verapamil, alone and in combination with propranolol, for CPVT treatment.

Main Methods:

Assessed heart rhythm in CASQ2 mutant mice using telemetry during rest, exercise, and epinephrine challenge.
Tested various antiarrhythmic drugs, including Class I agents, beta-blockers, and calcium channel blockers.
Validated findings in human patients with CASQ2 mutations undergoing exercise testing.

Main Results:

CASQ2 mutant mice exhibited ventricular arrhythmias, with Class I agents and beta-blockers showing limited efficacy.
Verapamil demonstrated dose-dependent protection against CPVT in mice, superior to nifedipine.
Combination therapy with verapamil and propranolol enhanced antiarrhythmic effects in mice and attenuated arrhythmias in human patients.

Conclusions:

Verapamil is a potent agent against catecholamine-induced arrhythmias in a mouse model of CASQ2-related CPVT.
Verapamil may enhance beta-blocker efficacy in human patients with CPVT2, offering a potential therapeutic strategy.